Compare

Crescent Biopharma/$CBIO

1D1W1M3M6MYTD1Y5YMAX

About Crescent Biopharma

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Ticker
$CBIO
Sector
Health
Primary listing
NASDAQ
Employees
69
Headquarters
Waltham, United States
Website
crescentbiopharma.com

CBIO Metrics

BasicAdvanced
$632M
-
-$6.03
-
-

What the Analysts think about CBIO

Analyst ratings (Buy, Hold, Sell) for Crescent Biopharma stock.
Analyst projections of the future price of Crescent Biopharma stock.

Bulls say / Bears say

CR-001 has completed dose escalation in its global Phase 1/2 trial, with more than 125 patients treated across the US, Europe and South Korea. Crescent expects initial monotherapy data in Q1 2027, giving investors a near-term test of the lead programme. (Crescent Biopharma)
The company has started enrolling CR-001 chemotherapy-combination cohorts across several cancers, including lung, colorectal, biliary, gastric and endometrial tumours. Initial data from these expansion cohorts are expected in mid-2027, potentially showing whether the drug can be used across multiple settings. (Crescent Biopharma)
A July share offering lifted pro forma cash to $305.1 million, which Crescent says should fund operations into the second half of 2028. That provides financial cover for several planned clinical readouts before the company is likely to need more capital. (Crescent Biopharma)
CR-001 remains investigational, and its first reported response data are expected from a first-line lung cancer cohort of up to 12 patients. The first planned Phase 3 study is not expected to start until early 2028 and depends on trial results and regulatory discussions. (Crescent Biopharma)
The lead programme has yet to demonstrate clinical benefit, while Crescent says it faces competition from companies developing treatments for the same diseases. If CR-001 fails to show a clear advantage, its commercial opportunity and the value of the pipeline could be limited. (SEC)
Crescent has no approved products or sales revenue and reported a $24.8 million net loss in Q2 2026. It expects development costs to rise and warns that future fundraising may dilute shareholders, despite its current cash runway. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.

CBIO Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

CBIO Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing CBIO

Funds
Fund name
Fund size
$CBIO weighting
SPDR Russell 2000 US Small Cap€R2US
$5B0.01%
SPDR Russell 2000 US Small Cap£R2SC
$5B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.